Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus Radiotherapy for Refractory Pituitary Adenomas
NCT04244708Phase 3Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of temozolomide in pituitary adenoma, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
temozolomide
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on NCT04244708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244708.